<SEC-DOCUMENT>0001162194-23-000053.txt : 20230728
<SEC-HEADER>0001162194-23-000053.hdr.sgml : 20230728
<ACCEPTANCE-DATETIME>20230728170507
ACCESSION NUMBER:		0001162194-23-000053
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20230724
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FILED AS OF DATE:		20230728
DATE AS OF CHANGE:		20230728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STANDARD BIOTOOLS INC.
		CENTRAL INDEX KEY:			0001162194
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				770513190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34180
		FILM NUMBER:		231123978

	BUSINESS ADDRESS:	
		STREET 1:		2 TOWER PLACE
		STREET 2:		SUITE 2000
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6502666000

	MAIL ADDRESS:	
		STREET 1:		2 TOWER PLACE
		STREET 2:		SUITE 2000
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLUIDIGM CORP
		DATE OF NAME CHANGE:	20011113
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lab-20230724.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:38530f3d-0a7a-4968-a562-88fde0cd7cb1,g:244e6457-5065-4de5-9fa8-285d32dd0093,d:c819db4b5de44233878135cae33b347d--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lab-20230724</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001162194</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lab-20230724.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001162194</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-24</xbrli:startDate><xbrli:endDate>2023-07-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic819db4b5de44233878135cae33b347d_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WASHINGTON, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">D.C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of report (Date of earliest event reported)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">July 24, 2023</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Standard BioTools Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in Charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-34180</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">77-0513190</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></div><div style="margin-bottom:1.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission</span></div><div style="margin-bottom:1.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:1.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2 Tower Place</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 2000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">650)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">266-6000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> General Instruction A.2. below):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">LAB</ix:nonNumeric></span></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ic819db4b5de44233878135cae33b347d_46"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">2023 Change of Control and Severance Plan</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2023, the board of directors (the &#8220;Board&#8221;) of Standard BioTools Inc. (the &#8220;Company&#8221;) approved the Company&#8217;s 2023 Change of Control and Severance Plan (the &#8220;2023 Severance Plan&#8221;), which renews and amends, the Company&#8217;s 2020 Change of Control and Severance Plan (the &#8220;2020 Severance Plan&#8221;) previously adopted and approved by the Board. For the Chief Executive Officer (the &#8220;CEO&#8221;) and participants at the executive leadership team (the &#8220;ELT&#8221;) level, the 2023 Severance Plan has an initial three-year term and automatically renews thereafter for successive one-year periods. For participants at the Vice President level, the 2023 Severance Plan has an initial one-year term and expires unless explicitly renewed by the Compensation Committee of the Board. The 2023 Severance Plan is intended to provide certain payments of cash severance and other benefits to the Company&#8217;s executives in the event of a qualifying termination of employment with the Company. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s named executive officers, other members of its ELT, and certain other designated employees are eligible to participate in the 2023 Severance Plan and to receive benefits thereunder. On July 24, 2023, the Board approved the Company to enter into a participation agreement under the 2023 Severance Plan (the &#8220;Participation Agreement&#8221;) with Michael Egholm, Ph.D., the Company&#8217;s CEO. In addition, each of Hanjoon Alex Kim (the Company&#8217;s Chief Operating Officer), Jeffrey G. Black (the Company&#8217;s Chief Financial Officer), and Jeremy Davis (the Company&#8217;s Chief Commercial Officer) (together, the &#8220;Non-CEO Executives&#8221;) have entered into participation agreements under the 2023 Severance Plan. The 2023 Severance Plan supersedes the severance and/or change in control related benefits provided under t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company&#8217;s previous 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance Plan and any prior </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employment and severance agreements.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the 2023 Severance Plan, if the executive&#8217;s employment is terminated outside of the period beginning 3 months before a change of control (as defined in the 2023 Severance Plan) and ending 12 months after a change of control (such period, the &#8220;Change of Control Period&#8221;) for a reason other than cause (as defined in the 2023 Severance Plan) or the executive&#8217;s death or disability (as defined in the 2023 Severance Plan), then, subject to the Severance Conditions (as defined below), the executive will be entitled to receive the following severance benefits:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Continued payments (less applicable withholdings) totaling 75% of the executive&#8217;s annual base salary in effect as of the date of termination in equal installments over a period of nine months in the case of the Non-CEO Executives, or, in the case of the Company&#8217;s CEO, 200% of his annual base salary paid in equal installments over a period of 24 months.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Reimbursement of costs of continued health coverage for the executive, his or her spouse, and/or his or her dependents, as applicable, for a period of up to 9 months in the case of the Non-CEO Executives, or, in the case of the Company&#8217;s CEO, 12 months.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Reasonable outplacement services in accordance with any applicable policy of the Company that is in effect as of the executive&#8217;s termination (or if no such policy is in effect, as determined by the Company). </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the Company&#8217;s CEO, pursuant to Dr. Egholm&#8217;s Participation Agreement, 100% vesting acceleration of a number of unvested shares underlying Dr. Egholm&#8217;s then-outstanding equity awards that otherwise would vest during the period between his termination date and the one-year anniversary of his termination date (with the remainder forfeited on termination).</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the 2023 Severance Plan, if an executive&#8217;s employment is terminated within the Change of Control Period either (i) by the Company for a reason other than cause or the executive&#8217;s death or disability or (ii) by the executive for good reason (as defined in the executive&#8217;s participation agreement under the 2023 Severance Plan), then, subject to the Severance Conditions, the executive will be entitled to receive the following severance benefits:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lump-sum payment (less applicable withholdings) totaling 150% in the case of the Non-CEO Executives, or, in the case of the Company&#8217;s CEO, 250%, of the sum of (x) his or her annual base salary (as in effect immediately before termination or immediately before the change of control, whichever is higher) plus (y) the greater of (A) his or her annual target cash incentive (as in effect immediately before termination or immediately before the change of control, whichever is higher) or (B) the average of the annual cash incentives actually paid to him or her for the three fiscal years preceding the year in which his or her termination occurs.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A pro-rated payment of the executive&#8217;s annual target bonus in effect at the time of the Change of Control.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Reimbursement of costs for continued health coverage for the executive, his or her spouse, and/or his or her dependents, as applicable, for a period of up to 18 months in the case of the Non-CEO Executives, or, in the case of the Company&#8217;s CEO, 30 months.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the CEO and Non-CEO Executives, 100% vesting acceleration of his or her then-outstanding and unvested equity awards, provided that, if an equity award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless otherwise provided in the applicable equity award agreement, 100% of such equity award will vest assuming the applicable performance criteria had been achieved at target levels for the relevant performance period(s).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing descriptions of the 2023 Severance Plan and Participation Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the 2023 Severance Plan and Participation Agreement, as applicable, copies of which are filed as Exhibit 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Form of PSU Award Agreement</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 24, 2023, the Board approved the form of performance stock unit award agreement (the &#8220;Form of PSU Award Agreement&#8221;) for use in granting performance stock units under the Company&#8217;s 2011 Equity Incentive Plan. The Form of PSU Agreement provides for the grant of performance stock units with performance based vesting conditions as set forth in the PSU Agreement. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description of the Form of PSU Award Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Form of PSU Award Agreement, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Exhibits.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023changeofcontrolandsev.htm">2023 Change of Control and Severance Plan. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023severanceplanparticip.htm">2023 Change of Control and Severance Plan</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023severanceplanparticip.htm"> Participation Agreement</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023severanceplanparticip.htm">,</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023severanceplanparticip.htm"> by and between the Company and Michael Egholm, Ph.D.</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023severanceplanparticip.htm">,</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023severanceplanparticip.htm"> dated July 27, 2023.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="formofpsuawardagreement.htm">Form of PSU Award Agreement.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">______________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management compensation plan or arrangement. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURE</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: July 28, 2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STANDARD BIOTOOLS INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Jeffrey Black</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Black</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a2023changeofcontrolandsev.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5b52464e8f01426db585f75a80ab4ccc_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC.<br>2023 CHANGE OF CONTROL AND SEVERANCE PLAN<br>AND SUMMARY PLAN DESCRIPTION</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Adopted August 4, 2023</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.9pt">Introduction</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The purpose of this Standard BioTools Inc. 2023 Change of Control and Severance Plan, or Plan (as defined in Section 2 below), is to provide assurances of specified benefits to certain employees of the Company whose employment is subject to being involuntarily terminated other than for death, Disability, or Cause or voluntarily terminated for Good Reason under the circumstances described herein.  This Plan is an &#8220;employee welfare benefit plan,&#8221; as defined in Section 3(1) of the U.S. Employee Retirement Income Security Act of 1974, as amended (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">ERISA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This document constitutes both the written instrument under which the Plan is maintained and the required summary plan description for the Plan.  This Plan is a replacement for that certain Fluidigm Corporation Change of Control and Severance Plan and Summary Plan Description adopted by the Compensation Committee of Fluidigm Corporation on August 4, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prior Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Prior Plan expires according to its terms and will not be renewed.  By becoming a Participant under this Plan (and immediately upon execution of the Participation Agreement), the Participant expressly acknowledges that Participant will cease being a participant under or entitled to any benefits under the Prior Plan</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.9pt">Important Terms</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following words and phrases, when the initial letter of the term is capitalized, will have the meanings set forth in this Section 2, unless a different meaning is plainly required by the context&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.8pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Administrator</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Company, acting through the Compensation Committee or another duly constituted committee of members of the Board, or any person to whom the Administrator has delegated any authority or responsibility with respect to the Plan pursuant to Section 12, but only to the extent of such delegation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.8pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.8pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; exists upon (i) a Participant&#8217;s conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony&#59; or (ii) a Participant&#8217;s (a) engagement in material dishonesty, willful misconduct, or gross negligence&#8212;in each case in connection with the Participant&#8217;s position at the Company&#59; (b) breach of any confidentiality, invention assignment, non-disclosure, or non-solicitation agreement entered into between the Company and the Participant&#59; (c) material violation of a written Company policy or procedure that has been provided to the Participant, which violation causes substantial injury to the Company&#59; or (d) willful refusal to perform the Participant&#8217;s assigned duties to the Company, following written notice of such refusal by the Company and a period of fifteen (15) days to cure the same and the Participant&#8217;s failure to cure during such time period.  No act or omission shall be considered &#8220;willful&#8221; if such act or omission was done, or not done, in the reasonable, good-faith belief that such act or omission was in the best interests of the Company or upon the advice of counsel to the Company.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:90pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;padding-left:0.36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.96pt">&#8220;Change of Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.7pt">Change in Ownership of the Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A change in the ownership of the Company that occurs on the date that any one person, or more than one person acting as a group (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than fifty percent (50%) of the total voting power of the stock of the Company&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that for purposes of this subsection, the acquisition of additional stock by any one Person considered to own more than fifty percent (50%) of the total voting power of the stock of the Company will not be considered a Change in Control.  Further, if the stockholders of the Company immediately before such change in ownership continue to retain immediately after the change in ownership direct or indirect beneficial ownership of fifty percent (50%) or more of the total voting power of the stock of the Company or of the ultimate parent entity of the Company in substantially the same proportions as their ownership of the Company&#8217;s voting stock immediately prior to the change in ownership, such event shall not be considered a Change in Control under this subsection.  For this purpose, indirect beneficial ownership shall include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities that own the Company, as the case may be, either directly or through one or more subsidiary corporations or other business entities.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.7pt">Change in Effective Control of the Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. A change in the effective control of the Company that occurs on the date that a majority of members of the Board is replaced during any twenty-four (24) month period with individuals whose appointment or election to the Board is not endorsed by a majority of the members of the Board prior to the date of the appointment or election.  For purposes of this subsection (b), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control&#59; or</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.7pt">Change in Ownership of a Substantial Portion of the Company&#8217;s Assets</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A change in the ownership of a substantial portion of the Company&#8217;s assets that occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such Person) assets from the Company that have a total gross fair market value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that for purposes of this subsection 2.4.3, the following will not constitute a change in the ownership of a substantial portion of the Company&#8217;s assets&#58;  (a) a transfer to an entity that is controlled by the Company&#8217;s stockholders immediately after the transfer&#59; or (b) a transfer of assets by the Company to (i) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&#8217;s stock&#59; (ii) an entity as to which fifty percent (50%) or more of the total value or voting power is owned, directly or indirectly, by the Company&#59; (iii) a Person that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding stock of the Company&#59; or (iv) an entity as to which at least fifty percent (50%) of the total value or voting power is owned, directly or indirectly, by a Person described in 2.4.3(b)(iii).  For purposes of this subsection 2.4.3, &#8220;gross fair market value&#8221; means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Section 2.4, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Notwithstanding any of the foregoing, however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in any circumstance or transaction in which compensation or benefits paid under this Plan would result in imposition of an additional tax under Section 409A of the Code (as defined below) if the foregoing definition of &#8220;Change of Control&#8221; were to apply, but would not result in the imposition of any additional tax if the term &#8220;Change of Control&#8221; were defined herein to mean a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5), then &#8220;Change of Control&#8221; shall mean a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5), but only to the extent necessary to prevent such compensation from becoming subject to an additional tax under Section 409A.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Further and for the avoidance of doubt</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a transaction will not constitute a Change in Control if&#58;  (i) its primary purpose is to change the jurisdiction of the Company&#8217;s incorporation, or (ii) its primary purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.8pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change of Control Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the time period beginning three (3) months prior to a Change of Control (or three months prior to signing of a definitive agreement to consummate a Change of Control if the Company enters into such an agreement) and ending on the date that is twelve (12) months following the Change of Control.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.8pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986, as amended. Reference to a specific section of the Code or regulation thereunder shall include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.8pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Standard BioTools Inc. and any successor that assumes the obligations of the Company under the Plan by way of merger, acquisition, consolidation or other transaction.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.8pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that Participant has been unable to perform his or her Company duties as the result of Participant&#8217;s incapacity due to physical or mental illness, and such inability, at least twenty-six (26) weeks after its commencement, is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to Participant or Participant&#8217;s legal representative (such agreement as to acceptability not to be unreasonably withheld).  Termination resulting from Disability may only be effected after at least 30 days&#8217; written notice by the Company of its intention to terminate Participant&#8217;s employment.  In the event that Participant resumes the performance of substantially all of his or her duties hereunder before the termination of employment becomes effective, the notice of intent to terminate will automatically be deemed to have been revoked.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.8pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means August 4, 2023, which is the date the Plan was deemed effective by the Compensation Committee of the Board.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;padding-left:0.36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.39pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equity Awards</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Participant&#8217;s outstanding stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance stock units, and any other Company equity compensation awards.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Participant&#8217;s Participation Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Involuntary Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Non-COC Involuntary Termination or a COC Involuntary Termination, in each case, under the circumstances described in Section 4 or Section 5, as applicable.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an employee of the Company or of any parent or subsidiary of the Company who (a) has been designated by the Administrator to participate in the Plan and (b) has timely and properly executed and delivered a Participation Agreement to the Company.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Participation Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the individual agreement (as will be provided in separate cover as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) provided by the Administrator to a Participant under the Plan, which has been signed and accepted by the Participant.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Standard BioTools Inc. 2023 Change of Control and Severance Plan as set forth in this document and as hereafter amended from time to time.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.17.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Section 409A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Section 409A of the Code and the final regulations and any guidance promulgated thereunder.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.18.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 409A Limit</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means two (2) times the lesser of&#58; (i) the Participant&#8217;s annualized compensation based upon the annual rate of pay paid to the Participant during the taxable year preceding the taxable year of the Participant&#8217;s termination of employment as determined under, and with such adjustments as are set forth in, Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto&#59; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which the Participant&#8217;s employment is terminated.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.19.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severance Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the compensation and other benefits that the Participant will be provided in the circumstances described in Section 4 or Section 5 of the Plan, as applicable.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.9pt">Eligibility for Severance Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  An individual is eligible for Severance Benefits under the Plan, as described in Section 4 or Section 5, as applicable, only if he or she experiences an Involuntary Termination.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.9pt">Involuntary Termination Outside the Change of Control Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, outside of the Change of Control Period, the Company (or any parent or subsidiary of the Company) terminates the Participant&#8217;s employment for a reason other than for Cause, the Participant&#8217;s death or Disability (a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Non-COC Involuntary Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), subject to the Participant&#8217;s compliance with Section 7, the Participant will receive the following Severance Benefits&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;padding-left:0.36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.96pt">Cash Severance Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Continued payments of cash severance for the period set forth in the Participant&#8217;s Participation Agreement&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.8pt">Continued Medical Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Participant and any spouse and&#47;or other dependents of the Participant (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Family Members</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) have coverage on the date of the Participant&#8217;s Involuntary Termination under a group health plan sponsored by the Company, the Company will pay on behalf of Participant the total applicable premium cost for continued group health plan coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">COBRA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) during the period of time following the Participant&#8217;s employment termination, as set forth in the Participant&#8217;s Participation Agreement, provided that the Participant validly elects and is eligible to continue coverage under COBRA for the Participant and any such Family Members&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.8pt">Outplacement Services</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Reasonable outplacement services in accordance with any applicable Company policy in effect as of the Participant&#8217;s Non-COC Involuntary Termination (or if no such policy is in effect, as determined by the Company, in its sole discretion).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.9pt">Involuntary Termination During the Change of Control Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, during the Change of Control Period, (i) a Participant terminates his or her employment with the Company (or any parent or subsidiary of the Company) for Good Reason, or (ii) the Company (or any parent or subsidiary of the Company) terminates the Participant&#8217;s employment for a reason other than Cause or the Participant&#8217;s death or Disability (a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">COC Involuntary Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then, in each case, subject to the Participant&#8217;s compliance with Section 7, the Participant will receive the following Severance Benefits&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.8pt">Cash Severance Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A lump-sum payment of cash severance and&#47;or bonus equal to the amount set forth in the Participant&#8217;s Participation Agreement&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.8pt">Equity Award Vesting Acceleration Benefit</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant&#8217;s Equity Awards will accelerate and vest to the amount set forth in the Participant&#8217;s Participation Agreement, as applicable&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.8pt">Continued Medical Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Participant, and any Family Member(s) has&#47;have coverage on the date of the Participant&#8217;s Involuntary Termination under a group health plan sponsored by the Company, the Company will pay on behalf of Participant the total applicable premium cost for continued group health plan coverage under the COBRA during the period of time following the Participant&#8217;s employment termination, as set forth in the Participant&#8217;s Participation Agreement, provided that the Participant validly elects and is eligible to continue coverage under COBRA for the Participant and his or her Family Members&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.8pt">Outplacement Services</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Reasonable outplacement services in accordance with any applicable Company policy in effect as of the Participant&#8217;s COC Involuntary Termination (or if no such policy is in effect, as determined by the Company, in its sole discretion)&#59; provided, however, that such outplacement services shall be in no case less than the outplacement services provided under any applicable Company policy in effect immediately prior to the applicable Change of Control.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;padding-left:0.36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.3pt">Limitation on Payments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the severance and other benefits provided for in this Plan or otherwise (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">280G Payments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) payable to a Participant (i) constitute &#8220;parachute payments&#8221; within the meaning of Section 280G of the Code, and (ii) but for this Section 6, would be subject to the excise tax imposed by Section 4999 of the Code, then the 280G Payments will be either&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.8pt">delivered in full, or</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.8pt">delivered as to such lesser extent as would result in no portion of such benefits being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by the Participant on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999. If a reduction in severance and other benefits constituting &#8220;parachute payments&#8221; is necessary so that benefits are delivered to a lesser extent, reduction will occur in the following order&#58; (a) cancellation of awards granted &#8220;contingent on a change in ownership or control&#8221; (within the meaning of Code Section 280G)&#59; (b) a pro rata reduction of (i) cash payments that are subject to Section 409A as deferred compensation and (ii) cash payments not subject to Section 409A&#59; (c) a pro rata reduction of (i) employee benefits that are subject to Section 409A as deferred compensation and (ii) employee benefits not subject to Section 409A&#59; and (d) a pro rata cancellation of (i) accelerated vesting equity awards that are subject to Section 409A as deferred compensation and (ii) equity awards not subject to Section 409A.  In the event that acceleration of vesting of equity awards is to be cancelled, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Participant&#8217;s equity awards.  Notwithstanding the foregoing, to the extent the Company submits any payment or benefit payable to the Participant under this Plan or otherwise to the Company&#8217;s stockholders for approval in accordance with Treasury Regulation Section 1.280G-1 Q&#38;A 7, the foregoing provisions shall not apply following such submission and such payments and benefits will be treated in accordance with the results of such vote, except that any reduction in, or waiver of, such payments or benefits required by such vote will be applied without any application of discretion by the Participant and in the order prescribed by this Section 6.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 6 will be made in writing by the Company&#8217;s independent public accountants immediately prior to the Change of Control or such other person or entity to which the parties mutually agree (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Firm</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), whose determination will be conclusive and binding upon the Participant and the Company.  For purposes of making the calculations required by this Section 6 the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.  The Participant and the Company will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section 6.  The Company will bear all costs the Firm may incur in connection with any calculations contemplated by this Section 6.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;padding-left:0.36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.3pt">Conditions to Receipt of Severance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.8pt">Release Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition to receiving the Severance Benefits under this Plan, each Participant will be required to sign and not revoke a separation and release of claims agreement in substantially the form attached this Plan as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Release</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  In all cases, the Release must become effective and irrevocable no later than the 60th day following the Participant&#8217;s Involuntary Termination (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Release Deadline Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If the Release does not become effective and irrevocable by the Release Deadline Date, the Participant will forfeit any right to the Severance Benefits. In no event will the Severance Benefits be paid or provided until the Release becomes effective and irrevocable.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.8pt">Other Requirements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Participant&#8217;s receipt of Severance Benefits will be subject to the Participant continuing to comply with the provisions of this Section 7 and the terms of any confidentiality, proprietary information and inventions agreement and such other appropriate agreement between the Participant and the Company.  Severance Benefits under this Plan will terminate immediately for a Participant if the Participant, at any time, violates any such agreement and&#47;or the provisions of this Section 7.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.9pt">Timing of Severance Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Provided that the Release becomes effective and irrevocable by the Release Deadline Date and subject to Section 10, the Severance Benefits will be paid (or in the case of Severance Benefits scheduled to be paid installments, will commence) on the first Company payroll date following the Release Deadline Date (such payment date, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Severance Start Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and any severance payments or benefits otherwise payable to the Participant during the period immediately following the Participant&#8217;s termination of employment with the Company through the Severance Start Date will be paid in a lump sum to the Participant on the Severance Start Date, with any remaining payments to be made as provided in this Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.9pt">Exclusive Benefit</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The benefits provided under this Plan shall be the exclusive benefit for a Participant related to termination of employment and&#47;or change in control and shall supersede and replace any severance and&#47;or change in control benefits set forth in any offer letter, employment agreement and&#47;or severance agreement, including without limitation the Prior Plan. For the avoidance of doubt, if a Participant was otherwise eligible to participate in any other Company severance plan (whether or not subject to ERISA), then participation in this Plan will supersede and replace eligibility in such other plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Section 409A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">Notwithstanding anything to the contrary in this Plan, no severance payments or benefits to be paid or provided to a Participant, if any, under this Plan that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A (together, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Deferred Payments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be paid or provided until the Participant has a &#8220;separation from service&#8221; within the meaning of Section 409A.  Similarly, no severance payable to a Participant, if any, under this Plan that otherwise would be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A 1(b)(9) will be payable until the Participant has a &#8220;separation from service&#8221; within the meaning of Section 409A.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.75pt">It is intended that none of the severance payments or benefits under this Plan will constitute Deferred Payments but rather will be exempt from Section 409A as a payment that would fall within the &#8220;short-term deferral period&#8221; as described in Section 10.3 below or resulting from an involuntary separation from service as described in Section 10.4 below.  In no event will a Participant have discretion to determine the taxable year of payment of any Deferred Payment.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">Notwithstanding anything to the contrary in this Plan or in any Participation Agreement, if a Participant is a &#8220;specified employee&#8221; within the meaning of Section 409A at the time of the Participant&#8217;s separation from service (other than due to death), then the Deferred Payments, if any, that are payable within the first six (6) months following the Participant&#8217;s separation from service, will become payable on the date six (6) months and one (1) day following the date of the Participant&#8217;s separation from service.  All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.  Notwithstanding anything herein to the contrary, in the event of the Participant&#8217;s death following the Participant&#8217;s separation from service, but before the six-month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of the Participant&#8217;s death and all other Deferred Payments will be payable in accordance with the payment schedule applicable to each payment or benefit.  Each payment and benefit payable under this Plan is intended to constitute a separate payment under Section 1.409A-2(b)(2) of the Treasury Regulations.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">Any amount paid under this Plan that satisfies the requirements of the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">Any amount paid under this Plan that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Payments for purposes of Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.72pt">The foregoing provisions are intended to comply with or be exempt from the requirements of Section 409A so that none of the payments and benefits to be provided under the Plan will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply or be exempt.  Notwithstanding anything to the contrary in the Plan, including but not limited to Sections 12 and 15, the Company reserves the right to amend the Plan as it deems necessary or advisable, in its sole discretion and without the consent of the Participants, to comply with Section 409A or to avoid income recognition under Section 409A prior to the actual payment of benefits under the Plan or imposition of any additional tax.  In no event will the Company reimburse a Participant for any taxes that may be imposed on the Participant as result of Section 409A.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Withholdings</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will withhold from any payments or benefits under the Plan all applicable U.S. federal, state, local and non-U.S. taxes required to be withheld and any other required payroll deductions.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;padding-left:0.36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.73pt">Administration</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is the administrator of the Plan (within the meaning of section 3(16)(A) of ERISA).  The Plan will be administered and interpreted by the Administrator (in its sole discretion).  The Administrator is the &#8220;named fiduciary&#8221; of the Plan for purposes of ERISA and will be subject to the fiduciary standards of ERISA when acting in such capacity.  Any decision made or other action taken by the Administrator with respect to the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document, will be conclusive and binding on all persons and be given the maximum possible deference allowed by law.  In accordance with Section 2.1, the Administrator (a) may, in its sole discretion and on such terms and conditions as it may provide, delegate in writing to one or more officers of the Company all or any portion of its authority or responsibility with respect to the Plan, and (b) has the authority to act for the Company (in a non-fiduciary capacity) as to any matter pertaining to the Plan&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any Plan amendment or termination or any other action that reasonably could be expected to increase materially the cost of the Plan must be approved by the Board.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Eligibility to Participate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent that the Administrator has delegated administrative authority or responsibility to one or more officers of the Company in accordance with Sections 2.1 and 12, each such officer will not be excluded from participating in the Plan if otherwise eligible, but he or she is not entitled to act upon or make determinations regarding any matters pertaining specifically to his or her own benefit or eligibility under the Plan.  The Administrator will act upon and make determinations regarding any matters pertaining specifically to the benefit or eligibility of each such officer under the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Term</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Plan will have a term of three years commencing on the Effective Date for the CEO and ELT level positions and expiring on the third anniversary of the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Initial Term</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and shall, thereafter, automatically renew for successive one-year periods (each a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Renewal Term</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, collectively with the Initial Term, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) unless, upon the decision of the Administrator, the Company notifies the Participants who remain eligible for benefits under this Plan of the Plan&#8217;s nonrenewal at least twelve (12) months prior to the commencement of such Renewal Term, in which case such Renewal Term will be canceled and the Plan will expire on the anniversary of Initial Term or the relevant Renewal Term, as applicable.  VP level participants will have a term of one year commencing on the Effective Date and will expire unless explicitly renewed by the Compensation Committee of the Board.  If a Change of Control occurs, the Term will extend automatically through the date that is twelve (12) months following the effective date of the Change of Control.  If a Participant becomes entitled to benefits during the Term, the Plan will not terminate with respect to such Participant until all of the obligations of the Company and such Participant with respect to this Plan have been satisfied.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Amendment or Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company, by action of the Administrator, reserves the right to amend or terminate the Plan at any time, without advance notice to any Participant and without regard to the effect of the amendment or termination on any Participant or on any other individual.  Any amendment or termination of the Plan will be in writing.  In addition, notwithstanding the preceding, during the Term, the Company may not, without a Participant&#8217;s written consent, amend or terminate the Plan in any way, nor take any other action, that (i) prevents that Participant from becoming eligible for the Severance Benefits under the Plan, or (ii) reduces or alters to the detriment of the Participant the Severance Benefits payable, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or potentially payable, to a Participant under the Plan (including, without limitation, imposing additional conditions).  Any action of the Company in amending or terminating the Plan will be taken in a non-fiduciary capacity.</font></div><div style="margin-bottom:0.08pt;padding-left:0.36pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:21.73pt">Claims and Appeals</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:11.72pt">Claims Procedure</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any employee or other person who believes he or she is entitled to any payment under the Plan may submit a claim in writing to the Administrator within 90 days of the earlier of (i) the date the claimant learned the amount of his or her benefits under the Plan or (ii) the date the claimant learned that he or she will not be entitled to any benefits under the Plan.  If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based.  The notice also will describe any additional information needed to support the claim and the Plan&#8217;s procedures for appealing the denial.  The denial notice will be provided within 90 days after the claim is received.  If special circumstances require an extension of time (up to 90 days), written notice of the extension will be given within the initial 90-day period.  This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision on the claim.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:11.72pt">Appeal Procedure</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the claimant&#8217;s claim is denied, the claimant (or his or her authorized representative) may apply in writing to the Administrator for a review of the decision denying the claim.  Review must be requested within 60 days following the date the claimant received the written notice of their claim denial or else the claimant loses the right to review.  The claimant (or representative) then has the right to review and obtain copies of all documents and other information relevant to the claim, upon request and at no charge, and to submit issues and comments in writing.  The Administrator will provide written notice of its decision on review within 60 days after it receives a review request.  If additional time (up to 60 days) is needed to review the request, the claimant (or representative) will be given written notice of the reason for the delay.  This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision.  If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based.  The notice also will include a statement that the claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all documents and other information relevant to the claim and a statement regarding the claimant&#8217;s right to bring an action under Section 502(a) of ERISA.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The parties shall each bear their own expenses, legal fees and other fees incurred in connection with this Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Source of Payments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All payments under the Plan will be paid from the general funds of the Company&#59; no separate fund will be established under the Plan, and the Plan will have no assets.  No right of any person to receive any payment under the Plan will be any greater than the right of any other general unsecured creditor of the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;padding-left:0.36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.73pt">Inalienability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In no event may any current or former employee of the Company or any of its subsidiaries or affiliates sell, transfer, anticipate, assign or otherwise dispose of any right or interest under the Plan.  At no time will any such right or interest be subject to the claims of creditors nor liable to attachment, execution or other legal process.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">No Enlargement of Employment Rights</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the establishment or maintenance or amendment of the Plan, nor the making of any benefit payment hereunder, will be construed to confer upon any individual any right to continue to be an employee of the Company.  The Company expressly reserves the right to discharge any of its employees at any time, with or without cause.  However, as described in the Plan, a Participant may be entitled to benefits under the Plan depending upon the circumstances of his or her termination of employment.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Successors</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any successor to the Company of all or substantially all of the Company&#8217;s business and&#47;or assets (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or other transaction) will assume the obligations under the Plan and agree expressly to perform the obligations under the Plan in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession.  For all purposes under the Plan, the term &#8220;Company&#8221; will include any successor to the Company&#8217;s business and&#47;or assets which become bound by the terms of the Plan by operation of law, or otherwise.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Applicable Law</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provisions of the Plan will be construed, administered and enforced in accordance with ERISA and, to the extent applicable, the internal substantive laws of the state of California (but not its conflict of laws provisions).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Severability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any provision of the Plan is held invalid or unenforceable, its invalidity or unenforceability will not affect any other provision of the Plan, and the Plan will be construed and enforced as if such provision had not been included.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Headings</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Headings in this Plan document are for purposes of reference only and will not limit or otherwise affect the meaning hereof.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Indemnification</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company hereby agrees to indemnify and hold harmless the officers and employees of the Company, and the members of its Board, from all losses, claims, costs or other liabilities arising from their acts or omissions in connection with the administration, amendment or termination of the Plan, to the maximum extent permitted by applicable law.  This indemnity will cover all such liabilities, including judgments, settlements and costs of defense.  The Company will provide this indemnity from its own funds to the extent that insurance does not cover such liabilities.  This indemnity is in addition to and not in lieu of any other indemnity provided to such person by the Company.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Additional Information</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;padding-left:166.5pt;text-indent:-130.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan Name</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;Standard BioTools Inc. 2023 Change of Control and Severance Plan</font></div><div style="margin-bottom:6pt;padding-left:166.5pt;text-indent:-130.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan Sponsor</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;Standard BioTools Inc.<br>c&#47;o General Counsel<br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;padding-left:166.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2 Tower Place, Suite 2000<br>South San Francisco, CA 94080</font></div><div style="margin-bottom:6pt;padding-left:166.5pt;text-indent:-130.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Identification Numbers</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EIN</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; 77-0513190<br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PLAN</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  502</font></div><div style="margin-bottom:6pt;padding-left:166.5pt;text-indent:-130.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan Year</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;Company&#8217;s fiscal year</font></div><div style="margin-bottom:6pt;padding-left:166.5pt;text-indent:-130.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan Administrator</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;Standard BioTools Inc.<br>Attention&#58; Administrator of the Standard BioTools Inc. 2020 Change of Control and Severance Plan<br>2 Tower Place, Suite 2000<br>South San Francisco, CA 94080<br>650-266-6000</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agent for Service of<br>Legal Process</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;Standard BioTools Inc.</font></div><div style="margin-bottom:6pt;padding-left:166.5pt;text-indent:-130.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Attention&#58;  General Counsel<br>2020 Change of Control and Severance Plan<br>2 Tower Place, Suite 2000<br>South San Francisco, CA 94080<br>650-266-6000</font></div><div style="margin-bottom:6pt;padding-left:166.5pt;text-indent:-130.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Service of process also may be made upon the Administrator.</font></div><div style="margin-bottom:6pt;padding-left:166.5pt;text-indent:-130.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Type of Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;Severance Plan&#47;Employee Welfare Benefit Plan</font></div><div style="margin-bottom:6pt;padding-left:166.5pt;text-indent:-130.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan Costs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;The cost of the Plan is paid by the Employer.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.82pt">Statement of ERISA Rights</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As a Participant under the Plan, you have certain rights and protections under ERISA&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">You may examine (without charge) all Plan documents, including any amendments and copies of all documents filed with the U.S. Department of Labor.  These documents are available for your review in the Company&#8217;s Human Resources Department.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">You may obtain copies of all Plan documents and other Plan information upon written request to the Administrator.  A reasonable charge may be made for such copies.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to creating rights for Participants, ERISA imposes duties upon the people who are responsible for the operation of the Plan.  The people who operate the Plan (called &#8220;fiduciaries&#8221;) have a duty to do so prudently and in the interests of you and the other Participants.  No one, including the Company or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a benefit under the Plan or exercising your rights under ERISA.  If your claim for payments or benefits under the Plan is denied, in whole or in part, you must receive a written explanation of the reason for the denial.  You have the right to have the denial of your claim reviewed.  (The claim review procedure is explained in Section 16 above.)</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12 of 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:265.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND <br>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Under ERISA, there are steps you can take to enforce the above rights.  For example, if you request materials and do not receive them within 30 days, you may file suit in a federal court. In such a case, the court may require the Administrator to provide the materials and to pay you up to $110 a day until you receive the materials, unless the materials were not sent due to reasons beyond the control of the Administrator.  If you have a claim which is denied or ignored, in whole or in part, you may file suit in a federal court.  If it should happen that you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In any case, the court will decide who will pay court costs and legal fees.  If you are successful, the court may order the person you have sued to pay these costs and fees.  If you lose, the court may order you to pay these costs and fees, for example, if it finds that your claim is frivolous.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you have any questions regarding the Plan, please contact the Administrator.  If you have any questions about this statement or about your rights under ERISA, you may contact the nearest area office of the Employee Benefits Security Administration (formerly the Pension and Welfare Benefits Administration), U.S. Department of Labor, listed in your telephone directory, or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W. Washington, D.C. 20210.  You also may obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13 of 13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a2023severanceplanparticip.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i84add72b658544feaafc76684404d754_1"></div><div style="min-height:92.16pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CEO Participation Agreement</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Appendix A</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard BioTools Inc. 2023 Change of Control and Severance Plan<br>Participation Agreement</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard BioTools Inc. (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is pleased to inform you that you have been selected to participate in the Company&#8217;s 2023 Change of Control and Severance Plan (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as a Participant.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A copy of the Plan was delivered to you with this Participation Agreement.  Your participation in the Plan is subject to all of the terms and conditions of the Plan.  The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In order to actually become a participant in the Plan, you must complete and sign this Participation Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Definition of &#8220;Good Reason&#8221;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the occurrence of one or more of the following events effected without your prior consent, provided you terminate your employment with the Company within one (1) year following the initial existence of the &#8220;Good Reason&#8221; condition (discussed below)&#58; (i) the assignment to you of any duties or the reduction of your then-current duties, either of which results in a material diminution in your then-current position or responsibilities with the Company, including a requirement that you are required to report to a corporate officer or employee instead of reporting directly to the board of directors of the Company or, if the Company becomes a subsidiary of another corporation, the board of directors of the Company&#8217;s parent company&#59; (ii) a material reduction by the Company in your then-current base salary&#59; (iii) a material change in the geographic location at which you must perform services (for purposes of this Participation Agreement, your relocation to a facility or a location less than 25 miles from your then-present location shall not be considered a material change in geographic location)&#59; or (iv) any material breach by the Company of any material provision of this Participation Agreement.  You will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#8220;Good Reason&#8221; within 90 days of the initial existence of the grounds for &#8220;Good Reason&#8221; and a reasonable cure period of not less than 30 days following the date of such notice.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-COC Involuntary Termination</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If, outside of the Change of Control Period, you incur a Non-COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive&#58; </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.72pt">Cash Severance Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  An aggregate amount equal to 200% of your annual base salary in effect as of the date of your Non-COC Involuntary Termination paid in equal installments over a period of 24 months following your termination date.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.72pt">Continued Medical Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Payment by the Company of continued health coverage under COBRA for a period of 12 months following your termination of employment.</font></div><div style="margin-bottom:6pt;padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:0.36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="padding-left:265.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION &#8211; FORM OF CEO PARTICIPATION AGREEMENT</font></div><div style="padding-left:265.7pt"><font><br></font></div><div style="padding-left:265.7pt"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:0.36pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:125%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:8.36pt">Equity Award Vesting Acceleration</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Acceleration and vesting of a number of unvested shares underlying your then-outstanding equity awards that otherwise would vest during the period between your termination date and the one-year anniversary of your termination date (with the remainder forfeited on termination)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.72pt">Outplacement Services</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Outplacement services as described in Section 4.3 of the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COC Involuntary Termination</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.72pt">Cash Severance Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.24pt">A lump-sum payment equal to 250% of the sum of (x) your annual base salary (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), plus (y) the greater of (A) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, or (B) the average of the annual bonuses actually paid to you for the three (3) fiscal years preceding the year in which your COC Involuntary Termination occurs.  For the avoidance of doubt, if you incurred a termination prior to a Change of Control that qualifies as a COC Involuntary Termination, then you will be entitled to a lump-sum payment of the amount calculated under the preceding sentence, less amounts already paid as cash Severance Benefits for a Non-COC Involuntary Termination.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.68pt">A lump sum amount equal to (i) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), multiplied by (ii) a fraction, the numerator of which is the number of days worked by you during the year in which the COC Involuntary Termination occurs and the denominator of which is 365.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.72pt">Continued Medical Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Payment by the Company of continued health coverage under COBRA (or, for any period after expiration of COBRA eligibility, reimbursement of health insurance monthly costs up the amount of the COBRA premium that would be payable if COBRA were available at such time) for a period of 30 months following your termination of employment.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.72pt">Equity Award Vesting Acceleration</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  100% of your then-outstanding and unvested Equity Awards will become vested in full.  If, however, an outstanding Equity Award is to vest and&#47;or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless expressly otherwise provided in the applicable Equity Award agreement, the Equity Award will vest as to 100% of the &#8220;Baseline Number of Restricted Stock Units&#8221; or &#8220;Baseline Number of Performance Units&#8221; (as defined in the Company&#8217;s grant agreements) or the equivalent measure of the number of units or shares that vest at 100% of target levels of achievement under the relevant Equity Award.  Except otherwise provided in the applicable Equity Award agreement, shares owed upon such vesting (and exercise if applicable) of Equity Awards will issued to you as promptly as practicable and no more than 30 days after they become issuable (whether through the vesting acceleration alone or upon an</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="padding-left:265.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION &#8211; FORM OF CEO PARTICIPATION AGREEMENT</font></div><div style="padding-left:265.7pt"><font><br></font></div><div style="padding-left:265.7pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exercise of options following such vesting acceleration).  Notwithstanding the foregoing, to the extent that the payment or settlement of an Equity Award is subject to Section 409A, the Equity Award will be paid or settled in a manner that will meet the requirements of Section 409A such that the payment or settlement will not be subject to the additional tax or interest applicable under Section 409A.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.72pt">Outplacement Services</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Outplacement services as described in Section 5.4 of the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Additional Benefits</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to the foregoing benefits, in addition to the Plan benefits described above, if, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, the Company will reimburse your reasonable attorneys&#8217; fees incurred in connection with the review of the Release and any related separation agreements and documents, up to $8,000.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">General Provisions</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For clarity, any severance payments provided for herein that are based on annual base salary (and any reduction to base salary constituting &#8220;Good Reason&#8221;) shall be calculated without giving effect to any temporary reduction in base salary imposed by the Company or agreed to by you in connection with any global pandemic or comparable global or U.S. emergency that threatens the Company&#8217;s economic position.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable within the requisite period set forth in the Plan.</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of This Page Intentionally Left Blank&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="padding-left:265.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION &#8211; FORM OF CEO PARTICIPATION AGREEMENT</font></div><div style="padding-left:265.7pt"><font><br></font></div><div style="padding-left:265.7pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan.  Your signature below confirms that&#58; (1) you have received a copy of the 2023 Change of Control and Severance Plan and Summary Plan Description&#59; (2) you have carefully read this Participation Agreement and the 2023 Change of Control and Severance Plan and Summary Plan Description&#59; (3) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors&#59; and (4) participation in the Plan and this Participation Agreement replaces in its entirety any severance and&#47;or change of control provisions set forth in any offer letter, employment agreement and&#47;or Equity Award agreement, including, but not limited to, the Prior Plan and your Employment and Severance Agreement with the Company dated Jan 19, 2022., </font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">STANDARD BIOTOOLS INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Carlos Paya</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Carlos Paya</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Director</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">__________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PARTICIPANT</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael Egholm</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Michael Egholm</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7&#47;27&#47;2023</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date</font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attachment&#58;  Standard BioTools Inc. 2023 Change of Control and Severance Plan and Summary Plan Description</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to the Participation Agreement&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>formofpsuawardagreement.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i36f7eec9a61e411692c87c3cbf9f8c23_1"></div><div style="min-height:74.88pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="margin-top:3pt;padding-left:167.52pt;padding-right:167.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:166%">STANDARD BIOTOOLS INC. 2011 EQUITY INCENTIVE PLAN</font></div><div style="margin-top:0.15pt;padding-left:83.52pt;padding-right:83.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PERFORMANCE UNIT AWARD AGREEMENT</font></div><div style="margin-top:6pt;padding-left:83.55pt;padding-right:83.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> (U.S. participants)</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:24pt;padding-right:23.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise defined in this Performance Unit Award Agreement, including the Terms and Conditions of Performance Unit Grant attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), all capitalized terms have the meanings given to them in the Standard BioTools Inc. 2011 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:167.47pt;padding-right:167.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PART I</font></div><div><font><br></font></div><div style="padding-left:83.55pt;padding-right:83.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NOTICE OF PERFORMANCE UNIT GRANT</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.8pt;padding-left:66.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Participant Name&#58;</font><img alt="image_0a.jpg" src="image_0a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:329px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:24pt;padding-right:23.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You have been granted the right to receive an Award of Performance Units, subject to the terms and conditions of the Plan and this Award Agreement, as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:66.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Grant&#58;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:241px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:66.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Baseline Number</font></div><div style="padding-left:66.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of Performance Units&#58;</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;padding-left:66.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Period&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fiscal Year &#91;XXXX&#93;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:24pt;padding-right:23.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to any acceleration provisions contained in the Plan or set forth in the appendix accompanying this Award Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Appendix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Performance Units will vest only if and to the extent the performance condition described in the Appendix is achieved. Vesting in all instances is subject to Participant&#8217;s continuous status as a Service Provider through the earlier of</font></div><div style="padding-left:23.95pt;padding-right:23.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) the Certification Date (as defined in the Appendix) and (ii) the effective date of a Change in Control. In the event Participant ceases to be a Service Provider for any or no reason before such earlier date, the Performance Units and Participant&#8217;s right to acquire any Shares hereunder will immediately terminate.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:23.95pt;padding-right:23.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By accepting this Award, Participant expressly consents to the sale of Shares (or the withholding of Shares in the case of Section 16 Officers (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">)) to cover the Tax Withholding Obligations (and any associated broker or other fees) and agrees and acknowledges that Participant may not satisfy them by any means other than the method set forth in Section 7 of the Terms and Conditions of Performance Unit Grant, unless required to do so by the Administrator or pursuant to the Administrator&#8217;s express written consent.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:24pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. 062923</font></div></div></div><div id="i36f7eec9a61e411692c87c3cbf9f8c23_4"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="margin-top:3pt;padding-left:23.95pt;padding-right:23.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant has reviewed the Plan and this Award Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Award Agreement and fully understands all provisions of the Plan and this Award Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions relating to the Plan and this Award Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:24pt;padding-right:23.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By Participant&#8217;s signature and the signature of the Standard BioTools Inc. representative below, Participant and the Company agree that this Award of Performance Units is granted under and governed by the terms and conditions of the Plan and this Award Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTICIPANT&#58;&#160;&#160;&#160;&#160;STANDARD BIOTOOLS INC. CORPORATION&#58;</font></div><div><font><br></font></div><div style="margin-top:10.85pt;padding-left:24pt;padding-right:23.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Participant&#8217;s Name&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:5pt;padding-left:24pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Electronic Signature</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.9pt;padding-left:24pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.05pt;padding-left:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Acceptance Date</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Attachments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-top:0.25pt;padding-left:24pt;padding-right:190.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">Exhibit A &#8211; Terms and Conditions of Performance Unit Grant Appendix &#8211; Vesting Conditions</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> - 2 -</font></div></div></div><div id="i36f7eec9a61e411692c87c3cbf9f8c23_7"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="margin-top:3pt;padding-left:167.5pt;padding-right:167.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:83.57pt;padding-right:83.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS OF PERFORMANCE UNIT GRANT (FOR PARTICIPANTS IN THE U.S.)</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company hereby grants to the individual named in the Notice of Performance Unit Grant attached as Part I of this Award Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) an Award of Performance Units, subject to all of the terms and conditions in this Award Agreement and the Plan, which is incorporated herein by reference. Subject to Section 18 of the Plan, in the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this Award Agreement, the terms and conditions of the Plan will prevail.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Company&#8217;s Obligation to Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Performance Unit represents the right to receive a Share on the date it vests. Unless and until the Performance Units will have vested in the manner set forth in Section 3, Participant will have no right to payment of any such Shares. Prior to actual payment of any vested Performance Units, such Performance Unit will represent an unsecured obligation of the Company, payable (if at all) only from the general assets of the Company. Any Performance Units that vest in accordance with Sections 3 or 4 will be paid to Participant (or in the event of Participant&#8217;s death, to his or her estate) in whole Shares, subject to satisfaction of any applicable tax obligations as set forth in Section 7. Subject to the provisions of Section 4, such vested Performance Units will be paid in Shares as soon as practicable after vesting, but in each such case within the period ending no later than the date that is two and one-half (2&#189;) months from the end of the Company&#8217;s tax year that includes the vesting date.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as provided in Section 4, and subject to Section 5, the Performance Units awarded by this Award Agreement will vest in accordance with the vesting provisions set forth in the Notice of Grant. Performance Units scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest in Participant in accordance with any of the provisions of this Award Agreement, unless Participant will have been continuously a Service Provider from the Date of Grant until the date such vesting occurs.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Administrator Discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser portion of the balance, of the unvested Performance Units at any time, subject to the terms of the Plan. If so accelerated, such Performance Units will be considered as having vested as of the date specified by the Administrator.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything in the Plan or this Award Agreement to the contrary, if the vesting of the balance, or some lesser portion of the balance, of the Performance Units is accelerated in connection with Participant&#8217;s termination as a Service Provider (provided that such termination is a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">separation from service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; within the meaning of Section 409A, as determined by the Company), other than due to death, and if (x) Participant is a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">specified employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; within the meaning of Section 409A at the time of such termination as a Service Provider and (y) the payment of such accelerated Performance Units will result in the imposition of additional tax under Section 409A if paid to Participant on or within the six (6) month period following Participant&#8217;s termination as a Service Provider, then the payment of such accelerated Performance Units will not be made until the date six (6) months and one (1) day following the date of Participant&#8217;s termination as a Service Provider, unless the Participant dies following his or her termination as a Service Provider, in which case, the Performance Units will be paid </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%"> - A-1 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="padding-left:5.95pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in Shares to the Participant&#8217;s estate as soon as practicable following his or her death. It is the intent of this Award Agreement to comply with the requirements of Section 409A so that none of the Performance Units provided under this Award Agreement or Shares issuable thereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. For purposes of this Award Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Section 409A of the Code, and any proposed, temporary or final Treasury Regulations and Internal Revenue Service guidance thereunder, as each may be amended from time to time.</font></div><div style="padding-right:5.85pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="padding-left:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.75pt;text-decoration:underline">Forfeiture upon Termination of Status as a Service Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding any contrary provision of this Award Agreement, the balance of the Performance Units that have not vested as of the time of Participant&#8217;s termination as a Service Provider for any or no reason and Participant&#8217;s right to acquire any Shares hereunder will immediately terminate.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Death of Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any distribution or delivery to be made to Participant under this Award Agreement will, if Participant is then deceased, be made to Participant&#8217;s designated beneficiary, or if no beneficiary survives Participant, the administrator or executor of Participant&#8217;s estate. Any such transferee must furnish the Company with (a) written notice of his or her status as transferee, and</font></div><div style="padding-left:5.95pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) evidence satisfactory to the Company to establish the validity of the transfer and compliance with any laws or regulations pertaining to said transfer.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Default Method of Tax Withholding for Non-Section 16 Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If Participant is not a Section 16 Officer (as defined in subsection (b) below), the minimum federal, state, and local and foreign income, social insurance, payroll, employment and any other applicable taxes which the Company determines must be withheld with respect to this Award (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Tax Withholding Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) with respect to this Award will be satisfied by Shares being sold on Participant&#8217;s behalf at the prevailing market price pursuant to such procedures as the Company may specify from time to time, including through a broker- assisted arrangement (it being understood that the Shares to be sold must have vested pursuant to the terms of this Agreement and the Plan). The proceeds from the sale will be used to satisfy Participant&#8217;s Tax Withholding Obligation (and any associated broker or other fees) arising with respect to this Award. Only whole Shares will be sold to satisfy any Tax Withholding Obligation. Any proceeds from the sale of Shares in excess of the Tax Withholding Obligation (and any associated broker or other fees) will be paid to Participant in accordance with procedures the Company may specify from time to time. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By accepting this Award, Participant expressly consents to the sale of Shares to cover the Tax Withholding Obligations (and any associated broker or other fees) and agrees and acknowledges that Participant may not satisfy them by any means other than such sale of Shares, unless required to do so by the Administrator or pursuant to the Administrator&#8217;s express written consent.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Default Method of Tax Withholding for Section 16 Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event Participant is an employee of the Company or its Parent or Subsidiary who is subject to Section 16 of the Securities Exchange Act of 1934, as amended (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Section 16 Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Tax Withholding Obligation will be satisfied by the Company (or the employing or retaining Parent or Subsidiary) withholding from the number of Shares otherwise deliverable under this Award of Performance Units a number of Shares sufficient to pay such Tax Withholding Obligation&#59; provided, however, that the Shares to be withheld must have vested pursuant to the terms of this Award Agreement and the Plan. No fractional Shares will be retained to satisfy any portion of the Tax Withholding Obligation. Accordingly, if any withholding is</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%"> - A-2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">done through the withholding of Shares, Participant will pay to the Company (or the employing or retaining Parent or Subsidiary) an amount in cash sufficient to satisfy the remaining Tax Withholding Obligation due and payable as a result of the Company not retaining fractional Shares. Should the Company be unable to procure such cash amounts from Participant, Participant agrees and acknowledges that Participant is giving the Company (or the employing or retaining Parent or Subsidiary) permission to withhold from Participant&#8217;s paycheck(s) an amount equal to the remaining Tax Withholding Obligation due and payable as a result of the Company not retaining fractional Shares.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Administrator Discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Administrator determines that Participant cannot satisfy Participant&#8217;s Tax Withholding Obligation through the default procedure described in clauses (a) or (b), as applicable, it may permit Participant to satisfy Participant&#8217;s Tax Withholding Obligation by</font></div><div style="padding-left:5.95pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A) delivering to the Company Shares that Participant owns and that have vested with a Fair Market Value equal to the amount required to be withheld, (B) electing to have the Company withhold otherwise deliverable Shares having a value equal to the minimum amount statutorily required to be withheld, (C) payment by Participant in cash, or (D) such other means as the Administrator deems appropriate.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Company&#8217;s Obligation to Deliver Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For clarification purposes, in no event will the Company issue Participant any Shares unless and until arrangements satisfactory to the Administrator have been made for the payment of Participant&#8217;s Tax Withholding Obligation. If Participant fails to do so by the time they become due, Participant will permanently forfeit Participant&#8217;s Performance Units to which Participant&#8217;s Tax Withholding Obligation relates, as well as any right to receive Shares otherwise issuable pursuant to those Performance Units.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Rights as Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Neither Participant nor any person claiming under or through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares will have been issued, recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant. After such issuance, recordation and delivery, Participant will have all the rights of a stockholder of the Company with respect to voting such Shares and receipt of dividends and distributions on such Shares.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Guarantee of Continued Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF THE PERFORMANCE UNITS PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS AWARD OF PERFORMANCE UNITS OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AWARD AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND WILL NOT INTERFERE IN ANY WAY WITH PARTICIPANT&#8217;S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) TO TERMINATE PARTICIPANT&#8217;S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Address for Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any notice to be given to the Company under the terms of this Award Agreement will be addressed to the Company at Standard BioTools Inc., Two Tower Place, Suite 2000,</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%"> - A-3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="padding-left:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">South San Francisco, CA 94080, or at such other address as the Company may hereafter designate in writing.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Grant is Not Transferable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except to the limited extent provided in Section 6, this grant and the rights and privileges conferred hereby will not be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and will not be subject to sale under execution, attachment or similar process. Upon any attempt to transfer, assign, pledge, hypothecate or otherwise dispose of this grant, or any right or privilege conferred hereby, or upon any attempted sale under any execution, attachment or similar process, this grant and the rights and privileges conferred hereby immediately will become null and void.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the limitation on the transferability of this grant contained herein, this Award Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Additional Conditions to Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If at any time the Company will determine, in its discretion, that the listing, registration or qualification of the Shares upon any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory authority is necessary or desirable as a condition to the issuance of Shares to Participant (or his or her estate), such issuance will not occur unless and until such listing, registration, qualification, consent or approval will have been effected or obtained free of any conditions not acceptable to the Company. Where the Company determines that the delivery of the payment of any Shares will violate federal securities laws or other applicable laws, the Company will defer delivery until the earliest date at which the Company reasonably anticipates that the delivery of Shares will no longer cause such violation. The Company will make all reasonable efforts to meet the requirements of any such state or federal law or securities exchange and to obtain any such consent or approval of any such governmental authority.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Plan Governs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Award Agreement is subject to all terms and provisions of the Plan. In the event of a conflict between one or more provisions of this Award Agreement and one or more provisions of the Plan, the provisions of the Plan will govern. Capitalized terms used and not defined in this Award Agreement will have the meaning set forth in the Plan.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:5.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Administrator Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Administrator will have the power to interpret the Plan and this Award Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Performance Units have vested). All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Participant, the Company and all other interested persons. No member of the Administrator will be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Award Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company may, in its sole discretion, decide to deliver any documents related to Performance Units awarded under the Plan or future Performance Units that may be awarded under the Plan by electronic means or request Participant&#8217;s consent to participate in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div><font><br></font></div><div style="padding-right:5.85pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%"> - A-4 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.25pt;text-decoration:underline">Captions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction of this Award Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Agreement Severable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that any provision in this Award Agreement will be held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of this Award Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Modifications to the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Award Agreement constitutes the entire understanding of the parties on the subjects covered. Participant expressly warrants that he or she is not accepting this Award Agreement in reliance on any promises, representations, or inducements other than those contained herein. Modifications to this Award Agreement or the Plan can be made only in an express written contract executed by a duly authorized officer of the Company. Notwithstanding anything to the contrary in the Plan or this Award Agreement, the Company reserves the right to revise this Award Agreement as it deems necessary or advisable, in its sole discretion and without the consent of Participant, to comply with Section 409A or to otherwise avoid imposition of any additional tax or income recognition under Section 409A in connection to this Award of Performance Units.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Amendment, Suspension or Termination of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By accepting this Award, Participant expressly warrants that he or she has received an Award of Performance Units under the Plan, and has received, read and understood a description of the Plan. Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Company at any time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Award Agreement will be governed by the laws of the State of California, without giving effect to the conflict of law principles thereof. For purposes of litigating any dispute that arises under this Award of Performance Units or this Award Agreement, the parties hereby submit to and consent to the jurisdiction of the State of California, and agree that such litigation will be conducted in the courts of San Francisco County, California, or the federal courts for the United States for the Northern District of California, and no other courts, where this Award of Performance Units is made and&#47;or to be performed.</font></div><div style="margin-top:4.5pt;padding-left:167.5pt;padding-right:167.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">* * *</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%"> - A-5 -</font></div></div></div><div id="i36f7eec9a61e411692c87c3cbf9f8c23_10"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="margin-top:3.6pt;padding-left:190.8pt;padding-right:190.55pt;text-indent:36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">APPENDIX VESTING CONDITIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Award with Grant Date Target Value of $&#91;XXXX.XX&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Performance Stock Unit Award (&#8220;Award&#8221;) to &#91;NAME&#93; for &#91;XXXX&#93; performance stock units (&#8220;Units&#8221;), representing the right to receive the same number of shares of common stock of Standard BioTools Inc. (the &#8220;Company&#8221;), subject to the terms and conditions set forth below, the Grant Agreement and the Plan (as defined below).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Measuring Period and Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as provided under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below, the actual number of Performance Units that will become eligible to vest (if any) will be determined based on the achievement of the Performance Conditions on the earlier of (a) the date on which the Company files its Form 10-K for the year ended December 31, &#91;XXXX&#93; and (b) March 31, &#91;XXXX&#93; (such date, the &#8220;Vesting Date&#8221;). If the EBITDA Performance Condition (as defined below) is met for FY&#91;XXXX&#93;, 60% of the Units shall vest on the Vesting Date. If the Revenue Performance Condition (as defined below) is met for FY&#91;XXXX&#93;, 40% Units shall vest on the Vesting Date. If neither Performance Condition is fully met, none of the Units shall vest. Any unvested Units shall expire at 11&#58;59 pm on the Vesting Date. Any vested Units shall be settled by the Company within four days of the Vesting Date, at which point the Company shall issue &#91;NAME&#93; one share of the Company&#8217;s common stock for each such vested Unit.</font></div><div style="padding-right:11.5pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3. Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) &#8220;Committee&#8221; means the Compensation Committee of the Board of Directors of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) &#8220;EBITDA&#8221; mean the Company&#8217;s consolidated earnings, before interest (income or expense), taxes, depreciation, and amortization for FY&#91;XXXX&#93;, each calculated in accordance with U.S. GAAP and as set forth in the Company&#8217;s consolidated audited financial statements, taking into account any adjustment pursuant to Section 4 below.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) &#8220;EBITDA Performance Condition&#8221; means EBITDA of $&#91;XXXX&#93; for FY&#91;XXXX&#93;.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) &#8220;Performance Conditions&#8221; means the EBITDA Performance Condition together with the Revenue Performance Condition.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) &#8220;Plan&#8221; the Company&#8217;s 2011 Equity Incentive Plan, as amended.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f) &#8220;Revenue&#8221; means the Company&#8217;s consolidated revenue for FY&#91;XXXX&#93; calculated in accordance with U.S. GAAP and as set forth in the Company&#8217;s consolidated audited financial statements, taking into account any adjustment pursuant to Section 4 below.</font></div><div style="padding-right:11.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g) &#8220;Revenue Performance Condition&#8221; means Revenue of $&#91;XXXX&#93; for FY&#91;XXXX&#93;.</font></div><div style="padding-right:11.5pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4. Permitted Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. EBITDA and Revenue shall each be subject to equitable adjustment as the Committee deems appropriate in its sole discretion on account of any merger or acquisition of a company or business by the Company in FY&#91;XXXX&#93;.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5. Final Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Committee shall be responsible for determining in good faith whether the Performance Conditions set forth herein have been achieved.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6. ClawBack</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Following the vesting and settlement (if any) of the Units, any vested Units or shares of the Company&#8217;s common stock held by &#91;NAME&#93;as a result of vesting of the Units shall be subject to clawback by the Committee required pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Sarbanes-Oxley Act, or other applicable law, or rule or regulation of the U.S. Securities and Exchange Commission, as well as any implementing regulations or listing standards, as interpreted by the Committee in its sole discretion.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">Appendix - 1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7. Holding Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Following settlement of the Units, any shares of Company common stock held by &#91;NAME&#93; as a result of vesting of the Units shall be subject to a three-year holding period which shall commence on the Vesting Date and terminate on the three-year anniversary of the Vesting Date, subject to the terms and conditions set forth above and the Grant Agreement and the Plan. </font></div><div><font><br></font></div><div style="padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8. Change in Control. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if there is a Change in Control before the end of the Performance Period and Participant continues to be a Service Provider through the date of such Change in Control, then (i) the Performance Period will be shortened such that it ends on the date of the closing of the Change in Control, (ii) the Applicable Percentage will be the greater of (I) the Applicable Percentage otherwise calculated under the method set forth above based on the shortened Performance Period or (II) 100%, and (iii) Participant will vest in 100% of the Eligible Performance Units immediately prior to the closing of the Change in Control.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">Appendix - 2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>lab-20230724.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:38530f3d-0a7a-4968-a562-88fde0cd7cb1,g:244e6457-5065-4de5-9fa8-285d32dd0093-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lab="http://www.standardbio.com/20230724" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.standardbio.com/20230724">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lab-20230724_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lab-20230724_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.standardbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>lab-20230724_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:38530f3d-0a7a-4968-a562-88fde0cd7cb1,g:244e6457-5065-4de5-9fa8-285d32dd0093-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_8e710751-15a5-41cd-b55e-8b56a7fff749_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1187e06e-2f76-4690-9988-be5c7f0037ef_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_78ad7806-6c3c-42a3-9223-78024a986563_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_980befe3-0053-4cf0-a0ae-ff04b0665f52_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ed74d161-a658-4a33-9753-9714e19bad31_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_21b23dcf-3d34-499b-a995-1cf3d15bd173_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_216d9cdf-4b60-44d7-b3d3-f4c50ed0660d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_9765c154-93c1-47b9-88b1-b16e65e6652e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a0927de9-e0c6-4ce3-ad28-d17996733d69_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_266ba5a2-8f08-4954-9ea3-47fcdab1eb0c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_6418eeb8-c1cf-433f-af77-9b84a10e7790_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_05ab71e9-b78f-48c9-83bc-30150e1b2c1d_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_81411c65-c824-4c9c-99ab-c7755f76a211_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_047731a9-0219-4458-bb79-0d803dd08809_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cd6f8911-b9a8-4738-bb9d-e799312b3241_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f5e75499-55d1-4f99-9b78-889ee8f697d1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7bc51741-b65a-4b2c-be4a-a1c8ac904a38_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_58b403f5-d29e-4fd7-8612-b60f9f16573a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d1547c5a-a9c1-49fe-80ae-95c8db7f9696_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f97632a6-5b1a-4823-a177-3ccbcb5c57be_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2a09211f-8273-404f-bddb-0802c2d25bd2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_6eb10ddf-a202-4ad9-8127-f860677f4e56_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine3_e166a398-a165-4c5b-a965-6adc0a06e9d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine3_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3" xlink:to="lab_dei_EntityAddressAddressLine3" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bd36d5c6-50d1-4222-b5b5-c29742479098_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>lab-20230724_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:38530f3d-0a7a-4968-a562-88fde0cd7cb1,g:244e6457-5065-4de5-9fa8-285d32dd0093-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.standardbio.com/role/Cover" xlink:type="simple" xlink:href="lab-20230724.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.standardbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_58cb2553-e4fd-49c1-a8c1-c5f4153ee009" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_DocumentType_58cb2553-e4fd-49c1-a8c1-c5f4153ee009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_82bafa5c-614a-4bd2-9010-825db3bbaf4d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_DocumentPeriodEndDate_82bafa5c-614a-4bd2-9010-825db3bbaf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7e1fe9ac-06fd-4c6b-bd3a-534af2783992" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityRegistrantName_7e1fe9ac-06fd-4c6b-bd3a-534af2783992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bf5f8715-7b51-4fdd-a8b3-db813251dd89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bf5f8715-7b51-4fdd-a8b3-db813251dd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cf2c6443-aa0b-4c47-827d-e81d40f6ea55" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityFileNumber_cf2c6443-aa0b-4c47-827d-e81d40f6ea55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4d37269f-0fe8-4def-a5d5-e25fe6dfc2a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityAddressAddressLine1_4d37269f-0fe8-4def-a5d5-e25fe6dfc2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_496180e9-9b20-49e7-9f1e-6495e5dac7e9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityAddressAddressLine2_496180e9-9b20-49e7-9f1e-6495e5dac7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3_4d3775dc-70a1-4372-9273-f1bf94abd457" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityAddressAddressLine3_4d3775dc-70a1-4372-9273-f1bf94abd457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0c351447-d20f-4fd1-ae2a-72a707df37fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityAddressCityOrTown_0c351447-d20f-4fd1-ae2a-72a707df37fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7f7260b5-3975-4050-9e32-40bcb41fc689" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityAddressStateOrProvince_7f7260b5-3975-4050-9e32-40bcb41fc689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_230e874c-4844-4fdb-8654-9b8b88323055" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityAddressPostalZipCode_230e874c-4844-4fdb-8654-9b8b88323055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b62614f3-acf6-4d84-9cc1-948fb508be3c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_CityAreaCode_b62614f3-acf6-4d84-9cc1-948fb508be3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6f33af7a-6d73-4ec3-a030-e8ad63d5e289" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_LocalPhoneNumber_6f33af7a-6d73-4ec3-a030-e8ad63d5e289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_058527a9-7568-427b-862c-e9eac620f876" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_WrittenCommunications_058527a9-7568-427b-862c-e9eac620f876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_54846ece-3b0d-4cdd-a2ae-0b71421d161e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_SolicitingMaterial_54846ece-3b0d-4cdd-a2ae-0b71421d161e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a677f7e1-0d32-42e8-a28a-05e03dd22f52" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_PreCommencementTenderOffer_a677f7e1-0d32-42e8-a28a-05e03dd22f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a7a00497-1496-4504-915b-d1ef5bce654e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a7a00497-1496-4504-915b-d1ef5bce654e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4eff7e10-3291-4b37-a48e-90dae79466eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_Security12bTitle_4eff7e10-3291-4b37-a48e-90dae79466eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_24dcf02f-228c-4d51-a127-d97f770d4f76" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_TradingSymbol_24dcf02f-228c-4d51-a127-d97f770d4f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_907c2ad5-0907-4cd4-8d0d-3fbb7205f97d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_SecurityExchangeName_907c2ad5-0907-4cd4-8d0d-3fbb7205f97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8c74c954-6d09-49b6-8d78-766c540e2830" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityEmergingGrowthCompany_8c74c954-6d09-49b6-8d78-766c540e2830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b841d7d0-5b4b-4a1c-8b4b-9723794950e1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityCentralIndexKey_b841d7d0-5b4b-4a1c-8b4b-9723794950e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e28ec57c-0176-407a-b26e-acb08a1e0c63" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_AmendmentFlag_e28ec57c-0176-407a-b26e-acb08a1e0c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8ca6fae0-47aa-4bb0-a2cd-ad45c149fcca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15f5f49d-5ee2-443e-80d1-b09a65a4d3b7" xlink:to="loc_dei_EntityTaxIdentificationNumber_8ca6fae0-47aa-4bb0-a2cd-ad45c149fcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  !K0    $" (   ! T$A3    +$E$051X7NW!
M 0$   @"(/^?UA\%)                   P'4%     %X:>3$)$0ZJ+.<
+    245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
MB5!.1PT*&@H    -24A$4@  !.L    $" (   !0HRQ7    -4E$051X7NW7
M,0T   @$,?R;?L** DC:\1Q<%0   )R79"<    XR,$"  #PPQQL    X(,&
4E+&\"5Y1M(      245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_5.jpg
<TEXT>
begin 644 image_5.jpg
MB5!.1PT*&@H    -24A$4@   S    0@" (   "V&RY9   2JDE$051X7NW6
M,0$ , R L/HWW?X3,)[D1 &S  "DY@T  /QER   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!F
MR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!FR   8H8, "!V
4L 3;==Q-8Q<     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139742303694352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 24,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Standard BioTools Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Tower Place<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">266-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LAB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001162194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0513190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>lab-20230724_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lab-20230724.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001162194</identifier>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-07-24</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001162194</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-07-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Standard BioTools Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-34180</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">77-0513190</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2 Tower Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 2000</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">266-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">LAB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MT]O1KQC3W@+@**>_RX19^D%Z#PK0[6""<JX:I[9%L"W=6&WT#/?I'=H82L&
MSSY %;R2#Z(9"I<"?Z6TQ^A5%R.KC9_AGCV"\DS*$KU/^;*1!Q=H':3:\=E1
M*X 9?R4/"1#)Q<[UD8[4(GEQ<1J=TPZ]:NQ)X=ZBU_^!\)'[Q+$D%0M0B\XN
M0-QLU^3; Z?S<AT\UPY6U>7N2G!P-'\#7%]H[=X._-*Z^F=D^ ]02P,$%
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
M+AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*
M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC
M)8QQ8K3^-8+)#^Q^ %!+ P04    " "CB/Q6JL0B%C,!   B @  #P   'AL
M+W=O<FMB;V]K+GAM;(U1T6[", S\E2H?L!:T(0U17D#;D*8-C8GWT+K4(HDK
MQX6-KY_;JAK27O:4W-FZW%T6%^+3@>B4?'D78FYJD6:>IK&HP=MX1PT$G53$
MWHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7<P.6/$
M SJ4[]ST=P<F\1C0XQ7*W&0FB35=7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7F?RT
MA]@S8@\?5HWD9I:I8(4<I=_H]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.G8RF2&]B
M]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9J
MZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48
M<?R>Y0]02P,$%     @ HXC\5B0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%
MK@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J
M%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I
M2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC
M":[?#'!X=/X!4$L#!!0    ( *.(_%9ED'F2&0$  ,\#   3    6T-O;G1E
M;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:
MTMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)
M_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*
M&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7H
MK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*
M30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[
MQA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ HXC\5@=!36*!
M    L0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"
M% ,4    " "CB/Q6(=P&#^\    K @  $0              @ &O    9&]C
M4')O<',O8V]R92YX;6Q02P$"% ,4    " "CB/Q6F5R<(Q &  "<)P  $P
M            @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M *.(_%8CX21J700  "41   8              " @0X(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " "CB/Q6GZ ;\+$"  #B#   #0
M            @ &A#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *.(_%:7
MBKL<P    !,"   +              "  7T/  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( *.(_%:JQ"(6,P$  "("   /              "  680  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "CB/Q6)!Z;HJT   #X 0  &@
M        @ '&$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "CB/Q699!YDAD!  #/ P  $P              @ &K$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #U$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lab-20230724.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.standardbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lab-20230724.htm">lab-20230724.htm</File>
    <File>a2023changeofcontrolandsev.htm</File>
    <File>a2023severanceplanparticip.htm</File>
    <File>formofpsuawardagreement.htm</File>
    <File>lab-20230724.xsd</File>
    <File>lab-20230724_lab.xml</File>
    <File>lab-20230724_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lab-20230724.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "lab-20230724.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lab-20230724_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lab-20230724_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lab-20230724.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lab",
   "nsuri": "http://www.standardbio.com/20230724",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lab-20230724.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.standardbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lab-20230724.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.standardbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001162194-23-000053-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001162194-23-000053-xbrl.zip
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M@RI0*:68$,_)P&6M*2^I%]ZD2%*#R\':TXIQ410PAV5C-RS<3T3'&=@,!$G
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M&^ND0W#.;K[]5CONQI;R)YO@^+"VZD;Y/<Z2O%TL]VJP/L3Q,>#W"&S5:5F
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M(8/N=783!U4]P1(M_#FJT>KHIS,-GU$Y@JA97U=>HL\$>Q4M:"JZ=B6F-_.
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MVW>C[4/RY,G>P<GA\>&S@Y!I?U?1!U=[O/5CFNT?X'J1_O!/K39/>>A&:V;
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M IIMP8?,,D/1LF23=_!,=]Q]S(2FH])*'G8+=-4R?TROVZ#YEA>M/;-0U=1
MTJI)Q:'+)I872?LAR3V4!BK1 7GCN0GW60!F71HGOY"Q]J+>E=7%(S(2V5!Y
MD+XK*(IEW;8!C7(/K#;ZAK7'KM*;9W+[JGS<QLW78;=SSYFCS] +X  O\0SK
M/#UX'\Y**&;P.XR@RRPL4QJ@/K&=AAUS=!0Z@B 4,* 9[$3,IB*^1:3Z/;R/
MZQZL@I]OU#2!():AN.&>_YC.S"JVVAK$0_4AW/MN^*IF:*D_*@OI*[C4JEF>
M.P"^6.::J=<_JDG34&@0)A61$ P)7D,,6M1E.H<73W82Q)Z_#K9&>2'X7L;-
MX9E A-4 @_U\["%K H%*9I1+OEH8J@910I EA5[ILH\FO,:=&.5(X5D]DDIV
M5K50-(!TM9 E8A3/21##(+.=UE2MST('>^537[ MQ.K%R!^W%79O%LH%/7HM
M8 TPK!;!.D2%!KJL#V,MKR@%70@(B"@]!XZC2]\BDL<L8<3V,3IWH(8^%3 6
MSRT@]P@"5&205<Y55_!XWL&WD<O!2X@4$0CR$]O8P.U<PBS5VN<D@D*;<,>L
M#@6.EDM@O[0N,?]J+1_A!:OQ)CE63QC'7/#3/'>@]Z]N>_.+@1THL!/V*S%"
M&4'#.%HU/#(/J3&*ATX36G"!I$3=$#@*%UVOX9+PZ4Q0_!2/*ICO-J2&Z(<V
M#U8QOI5$.A*)E?LSMK7WT_/>R2E(W 40]#S*#HD(W,+)2'<&5W"%,'35+*7$
M"T7->MS4ZX9BY5M\W%7 ].]/T.Q_-X*F30![D"M?#6Q@J6"EKDVW0(]XQ*.R
MFG98BR=%%<I$A2MTQ0P$7<'[[&-O<8@29#TS),ANZ%:,(]++2SQ3@ZY1>10A
M@3H4(E<#&[!)Z8 T(+54:YGZP0R 32-'")X9O<V)*R9#T-Q9!;>K5C4UM*Y:
M;%)&9H;/!@E4A0<V_":73&C)=IITRF )+XJSCC;D+M_FA#^L AD=EM+,6\9/
M#EK$3U1L9UU((8?5.?<B)Q3X3/-N@MS(R)A#VG33$78(UYKFL(@<!]#$,^4^
M$E6'DE?D0C"D$SCNB-6RE+;L,?5W$M1J$:C* 7'&,-^:7&7+O.NRX0P1KMD@
MW1HM,U-/$+^*)*D\&4#!.!T]')ZVKLAQ*1QOYF4XFMR2/:8Y64.8FPCZX[W&
M"!-8/W)7PM'AJL)&HOYV74QSJA0^>H^1D88\! 7?FSW@B:L$3EG'ABEQ$F@1
M2D*B2ELW.12>TF@K./U6*JQ);:33:+^%_3;M'*O>OD@LN4Y6(W$5J:FUP%%F
M&P*ZI$_.--D][5,Y E>HE<XH5NOTVQT;@N\F@M#QRO)"+0K.VM;7[;S6T-Y]
M2MF26"Q]N1+?R18QKG+HD+?C=R72J"8HRMM:J;0MR]5 ;]L47,/RP09-?(,N
M9M["A'-)E725_LA],O84@#(W9#@85<:])#YF33GROK*M(VU>&F-55<? E?@F
M5D)J?/"M\T9M>(J>(%>4U$Q[L)&QE-E6;QN^7UG#3M^H\5UL, 6M.A,/MA;0
M]41D=62Y/C9HD[PBGG82K,WH-.Z(1N$!3P<!N(MB3S0"H+_36X<!^!'/+RW,
MPRAJ#>EEF3/.Y -4T+)R.=:YZRI)E00HZ.#*YT;!Q5ASJ3H5#[/8P4)./0HZ
M6XT@5R5Y$4FE0P7(G6H5N53?4NR[LF<8L,F]C*)$^4<+F;)3430W"M*!1$?:
M34'W,'F%BZEWG<!;.A/7"]+&TUP.Y?:(S%ITV1N5BX>MK_%!M#*>:J]"&Y00
ME6V9.T2I<]<5V3[!F:'-!.$!.I1$@P//B$K#F6"Z=@*?C,1UXAOW.;PYQ"W$
M)T;HT0<ETH@FV'+E7,H.%>FCY,Y&*QJ3Q&$;\90J3Q"J0'C,X&>]'5GD*IOD
M?AUNFN18\BHWX?#9#+-VV":'S_$=#A^@YIGP*"V(')@32Y]!!K>F>D.S/J$*
MZSVUQC,OZ?IXO#:[ZYDU\7,=;8S+;A=C&GR;Z5U9=.%[+*+P!]P_#?IEC]I$
MIG?Y9<]1=RD<M6;I#^/1+CH7O6FBN 5J6#X8(>%*%QHA8ZY@BJ[1>O#PDA^M
MX-<@LQ*6!6N8@ BL;M@*4*M$1W2JB$#,X'ORSV%\>X:$9GT**A30))"UW5)'
M:U.%\@,J.1=_KZ9WI9"J=5&N@A#6%_%),%XX^6R6A-#@/)<Y28KE%M].RQ4$
M:3C*4ERS$CI9FZ0</ 9Y-E4F9[K-!/)%9+XI5D"JLV0O&>9)PX),?;.6-S!\
M%_.L#5/6:Z1Q5J"T>OE(FL]O:6E#2U]:JAB=3D*.R(>BVWE,SGE\K/;&9HD[
M#?+$X_;PQ./U#+%0-Z517OBP!^2.7*QO150T&&@!!M>68]4[ZMYQL,[%C*,'
M]H,J>@-,I5BB!_6V"QGLE LA-2N1AR7)B4HKKRC85*S7%"732#^$?)A2_G7M
M.92"BV3!9L)%=%J'A)$V37V)I2^I((0,82P!X70I$HKEBJAD7!*JP-:2KT*)
M\ET% 5*P+RG %.O(@\%@8933U.;]:< D4B)UJDM6"=]5[!VTX67J$DE5C*U6
M.B/J*S^UP#6QO6X]4P<4B6D=<-:VR%3@7"*8$T8=JA2EJ2",FXZN:+ SO@2,
M[XN(L1P*2&N[VA.I4V#2.<)--$;//A7HL5!!IE7979&_'$95&^2ZBM8.8BT]
M9=.%(5;34_D 7JRGH>NL2.F:ZA;"<DWB"N \Z2C:J-9BI2H+"(!K6 EVWU8H
M!YJE<"W$'Y5J,RN>1-H=ITMW5:UO_;FZ3T&QT*/+T>I/09==(GS5QGMF!P.7
MQ1HF=ED_+*4SU\P\5X9.?'7HJB!=<>PA)KH.$UN!Q+).X<9'L-M@/;R'KA3X
M7=6N([Z1GT#S=><>$ ]7J0JV6Q.<MDD3W-U["%6P=6I@71%8A(@$*0BC ",G
M_TA,CA 3@0*E$ QK=), DR\4_;4F;:I)80Z$"B4-OCJJ-FW?H>A:[W3_@ (,
M)JBPU3A497U\J!U;F2\"O4;:5>IC]MZ:^JYJ[PGK@NX/X_&HVO/M7#'85"8'
M='.#)1#L:_O(^4<*?,G+5UD,C)>;BQ)<=T^'7Y=<^]+J)__3\\/3EVE0M</F
M\A9./H%1JA2VU%RXK]*V)D\18Q&P0BJU!:R>@C*DUEF4%*("!'"M?D1:"'SJ
M*Z"A<1V:9[UF"TJT$3&RMFK$#\1(:6'NZ3S>X$I1Z*@Y1Z:+& R[NGQE:>N*
MU$)D.06/\S=Q3\P37LA$61$.C^8%UF8IL-#60K>UALDC"A2YCDDDI)BB1@L6
M1#DJR-GX2IRI"S]EXN=K.*)Q&2CGBR0K)S&EWVGP:B[:.,L%2W*%(3=5XSVZ
MXM)@]O[00B_1(Q1%.KO6;'-IH*FB#NOGS(7S92NR-PFL <3-R$;VX^E#LQN0
M;Y-6@M,F*^$N!$4[4V:&5;5W+?]IB20='MB&]3T]2S:K=;79E/I*\A>..#Y/
M$#J&84\8$YB$RC9(W;\=3"Q'0Y](.S_*;_=]35=_C&+:%2WM;QM]VZJ;;/B-
MT7B+6RQO-3(L@[5HY5?%1MD;[H7L@W+#_L)]X' YOJAYI>TZL53J#MMZO<T$
MW0VMQI3>:VR'NXD[5UL-!LZBDIPX1G:+0S#A"#T4BHS#R8857C.LL^T4D3Y=
M%3U\*-X(';!UOJT$GO(@*6^2=C47R4@LZ,"&<AEZCPRN^0Z=/&Z;V/==3I[U
MU3K.U?'41[-9EH[ 6V">87:+D('A4HY!(+7/A_18F^P01)S/9["X1%(LW6&%
M0J)*)$:>&+*D8D+ES+0.9Z6 W(]1E^*8,^[Y4<E-JQSL<X&:*\8<41^K4N<%
M>AQ@(%AI0T$=*\=3 ?V3.@!Y3SE#AC5N";".6^'[)-M@N4L554H.E!3KG7=%
MP :7A]<"S$&KP7TG[0&RW%'$883OD: 9Q]+Y@B>J:0_R!5 )BD";F@(-5@6"
M0I@J\"%OD89(59:LT@"KJPY8%0Q"-6&,K(1@ _KB6N41<)AHN@!%$\H+TBBD
MKAVCR<?6'S(<;(FI.>GM:R+*JO=0J#JK%52LDD!\$Q2($#<._=:ZP(/ZNUBB
MQWC0,_S9M4H3(:09\<LP4L )/6A1C#AV69_JS-"8B!T0=D+UIZ'$V>NKNLI(
M7/-_L])WK&TQQGLC2PN#O1+?6M+Z4TT^0;>/X' L%&B$:V277]HP_O5X?*KE
M-]"<?C>,ZD*RMPFGRSLH>(2W#GH!$(A!MC?+M*SJI*Q_]L^+RT_O!^=O!ZK(
M:?_M: "_3M[U)U2V])?!>#*\>(L53_'/8M73,?MX-1I?85.3R]P+X[-W@_.K
M]P/V;C :P-O#,1OT1Q>#<W9Y\?XS>_T9ZZG"DU?X<!\Z9^/!Z)<AM/MQ=/G+
M\'PP8GH(GX;OWYO^SRX_P+@_LZW+D1I/?S2 ON&O\=7K\?!\V!]]9H,/']]?
M?J91C]AH,.D/+_ /:][;-->+2^Q@='GU]ATUUC^;8#^O!_CTN^%H<-[1?U!M
M5QCZY!U,H_\);PZI* $[QO[Z9_^Z&HYH!=[!X,8T_ZL+F$]^Y=]<C:#/T5T[
MD/9''W^ R79HK!,8T1@&3.5H<25QTGT<8]H?M5:Y)>,!]'\)_=/#PPMV?DF+
M >W DY.K":S%!1O\^A'&3Y,:0N-#:!NVYL-P/,#)Z]V##P<7;_MO:6@U^_A&
M;Y89!ZS;\!+6%C_'S31_7]*6]]^_[]#0:=]Q6$.8W>@-C!1KZ>(+G_KP_R$,
M/W??"VF<8S8:OGU')P*[U'\\\.'!HSX8?1A>P()7CV'PGFZ1&;\;?JP_W#B6
MR?##H*,F _WAS\LKV(C^U7CPU+;R!J[.)JL%[[:&__?N]'.ZA'!1\%=,4VC8
M'NXKUSJB!97+YQJTHJ#H##.AZ+LBNB9<R]4TA5MLB,<U-V8!Z[J5;")O467V
M.6ILX\2+!=N#%>AL4F(_[TS<Z+;'OUQ =_]'0/=! KK5N;,-I<J.98)U2GG
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M0<,U3'I C6:WW3%HJVT;G<[ 9:;C'CA]JSKLV<TF:S=;!T;+;+>,ILM:1G=
M.X;=:;D-VW5-L]NHNCVG8W7=?K/?<EFS:3<:G8..U6@YE#4:_4;SP,5I1Q'@
M!SCZLO?0%Q[_6!E%4=BKU^_O[VOX2RT0P[IMFHTZ]V5$?8=5TO8>][\7VM\W
M5&NKV^W6U=.DZ>)&.'TZ'G^(RF?G/HS%D.#U2%!?(CUI! L"<-FF8=J&96=
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M-JD0[GZL# S;KAR9L+)6V[:Z %EAU#4F.089=E&./WMT6"%Z#3Y68-UZ _[
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ML5FSLF=U-;8>'U! LGRL@#XK8AD%(?0"L(D,/.Z2GTSU[S"DKLM]L(OA [$
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M+ ]*K1TO)J\8ZGDEN9M- U]&;N50]VO(FQ[TOX"\$O-YKAYO)M5XZ;AF:$_
M%S_.DM2B,2YOL$<H!APS D(8QD 9HP#D$&ML,%6F]3=C-,YR[) O'@2EV.!S
MVG77:,U83]2[VC4P[*V=Z@Y\G1/]D5^+^CS0UR76B'WMX/V!C\>150@:$P/I
M3 .A- )PA!F(>00CQN+04L_E?LTL/Q7X%[=9?_!Q#_"]['I.\+<YM1?P\4'
MQ\\//O8!'Q\ ?#*V*(HD$=PMY<LO+]>T_+H/]RB21D,)(RO:;V4USO)S@>^.
MLCV<\TD/]+T,>U;TMWJU%_C)0> GSP\_\8&?](;_J[U,R@]AI47UW<;*D,A0
M[9IY6&YA8XR!HHH"C04+<<@$%)Z[:.L3'"GRCR(]OR"ZUL2VA'>W9ABXV[K2
M >CZU'NP_"3@P!C7I[-)<,.X)GA7'7>X?W_[8OE,,O\/--Z^^#]02P,$%
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MSY@?1L6$2Y*[$W=GE+Q=/!+SE'8<OKD_T'UT_Z,Y?/,_4$L! A0#%     @
MHXC\5G#VF@2)-@  *',! !X              ( !     &$R,#(S8VAA;F=E
M;V9C;VYT<F]L86YD<V5V+FAT;5!+ 0(4 Q0    ( *.(_%:W@TX9CA   'QD
M   >              "  <4V  !A,C R,W-E=F5R86YC97!L86YP87)T:6-I
M<"YH=&U02P$"% ,4    " "CB/Q69;)AD^(F   0]@  &P
M@ &/1P  9F]R;6]F<'-U87=A<F1A9W)E96UE;G0N:'1M4$L! A0#%     @
MHXC\5HUU;#R3%P  I[,  !               ( !JFX  &QA8BTR,#(S,#<R
M-"YH=&U02P$"% ,4    " "CB/Q6L.FR%FP"  !V!P  $
M@ %KA@  ;&%B+3(P,C,P-S(T+GAS9%!+ 0(4 Q0    ( *.(_%8+-X/6Q H
M !!E   4              "  06)  !L86(M,C R,S W,C1?;&%B+GAM;%!+
M 0(4 Q0    ( *.(_%8P^9&X_@8  !<U   4              "  ?N3  !L
I86(M,C R,S W,C1?<')E+GAM;%!+!08     !P ' .$!   KFP     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
